NO20043871L - Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid - Google Patents

Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid

Info

Publication number
NO20043871L
NO20043871L NO20043871A NO20043871A NO20043871L NO 20043871 L NO20043871 L NO 20043871L NO 20043871 A NO20043871 A NO 20043871A NO 20043871 A NO20043871 A NO 20043871A NO 20043871 L NO20043871 L NO 20043871L
Authority
NO
Norway
Prior art keywords
controlled release
patient
formulations containing
release drug
drug formulations
Prior art date
Application number
NO20043871A
Other languages
English (en)
Norwegian (no)
Inventor
Jacques-Pierre Moreau
Roland Cherif-Cheikh
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of NO20043871L publication Critical patent/NO20043871L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20043871A 2002-03-04 2004-09-15 Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid NO20043871L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36159202P 2002-03-04 2002-03-04
PCT/US2003/006676 WO2003075887A1 (en) 2002-03-04 2003-03-04 Sustained release drug formulations containing a carrier peptide

Publications (1)

Publication Number Publication Date
NO20043871L true NO20043871L (no) 2004-09-15

Family

ID=27805051

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043871A NO20043871L (no) 2002-03-04 2004-09-15 Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid

Country Status (15)

Country Link
US (1) US7943575B2 (de)
EP (1) EP1480618B1 (de)
JP (1) JP2005525374A (de)
KR (1) KR20040091100A (de)
CN (1) CN1638732A (de)
AT (1) ATE432689T1 (de)
AU (1) AU2003224649B2 (de)
BR (1) BR0308137A (de)
CA (1) CA2474613A1 (de)
DE (1) DE60327843D1 (de)
ES (1) ES2327913T3 (de)
MX (1) MXPA04008240A (de)
NO (1) NO20043871L (de)
RU (1) RU2004129577A (de)
WO (1) WO2003075887A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
EP1539959A2 (de) * 2002-09-18 2005-06-15 Centre Hospitalier de l'Université de Montréal (CHUM) Ghrh-analoge
EP1589901A4 (de) * 2002-12-20 2006-08-09 Generipharm Inc Intrakutane injektion
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
UA88477C2 (ru) 2004-08-13 2009-10-26 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
ME01316B (me) * 2004-08-13 2013-12-20 Boehringer Ingelheim Int Formulacija tablete sa produženim oslobađanjem koji sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so
GB0428151D0 (en) 2004-12-22 2005-01-26 Novartis Ag Organic compounds
SI1881823T1 (sl) 2005-05-17 2015-04-30 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje bolezni oäśesa
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
EP2389930A1 (de) * 2006-03-31 2011-11-30 Erasmus University Medical Center Rotterdam Neue zusammensetzung zur kontrolle des tumorwachstums
EP2034951B2 (de) * 2006-06-22 2020-03-25 Biocompatibles UK Limited Rehydratisierbares pharmazeutisches produkt
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2702984C (en) 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US20120191039A1 (en) 2009-07-31 2012-07-26 Ascendis Pharma A/S Carrier linked pramipexole prodrugs
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9453020B2 (en) 2011-05-04 2016-09-27 Balance Therapeutics, Inc. Substituted pentylenetetrazoles as GABA receptor activity modulators
EP2877465A4 (de) 2012-07-25 2016-05-11 Sarcode Bioscience Inc Lfa-1-hemmer und polymorph davon
EP2958577A2 (de) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylat-cyclase-rezeptoragonisten zur verwendung bei der darmreinigung
WO2014152751A1 (en) * 2013-03-14 2014-09-25 Massachusetts Institute Of Technology Multi-layered injectable self-assembling peptide scaffold hydrogels for long-term sustained release of human antibodies
EP2968439A2 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Zusammensetzungen zur behandlung von magen-darm-störungen
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2926691A1 (en) 2013-10-10 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
EP3402804A1 (de) 2016-01-11 2018-11-21 Synergy Pharmaceuticals Inc. Formulierungen und verfahren zur behandlung von colitis ulcerosa
CN111885999A (zh) * 2018-03-15 2020-11-03 艾得佩索拉公司 凝胶形成性多肽
CN111195348A (zh) * 2018-11-19 2020-05-26 南京济群医药科技股份有限公司 一种生长抑素纳米混悬剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3484951D1 (de) 1983-10-14 1991-09-26 Sumitomo Pharma Verlaengerte praeparate mit verzoegerter abgabe.
CA1277601C (en) * 1985-12-27 1990-12-11 Shigeji Sato Method for producing sustained release formulation
US4863736A (en) 1987-03-16 1989-09-05 Monsanto Company Somatotropin prolonged release
GB2239178B (en) 1987-07-10 1991-11-27 Sandoz Ltd Somatostatin analogues for the treatment of breast cancer
GB8813339D0 (en) 1988-06-06 1988-07-13 Sandoz Ltd Improvements in/relating to organic compounds
US5252565A (en) 1990-04-02 1993-10-12 Merrell Dow Pharmaceuticals Inc. Haloethyl-substituted steroid enzyme inhibitors
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
EP0930876B2 (de) 1996-07-22 2010-07-07 Renovo Limited Verwendung von substanzen, die die östrogen wirkung fördern, zur beschleunigung der heilung von hautwunden
US5906987A (en) 1997-03-10 1999-05-25 Schering Aktiengesellschaft And Board Of Regents Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors

Also Published As

Publication number Publication date
EP1480618B1 (de) 2009-06-03
JP2005525374A (ja) 2005-08-25
KR20040091100A (ko) 2004-10-27
MXPA04008240A (es) 2004-12-07
RU2004129577A (ru) 2005-04-10
DE60327843D1 (de) 2009-07-16
BR0308137A (pt) 2005-01-04
AU2003224649B2 (en) 2006-09-07
US7943575B2 (en) 2011-05-17
US20050130900A1 (en) 2005-06-16
ES2327913T3 (es) 2009-11-05
WO2003075887A1 (en) 2003-09-18
CN1638732A (zh) 2005-07-13
EP1480618A1 (de) 2004-12-01
ATE432689T1 (de) 2009-06-15
CA2474613A1 (en) 2003-09-18
AU2003224649A1 (en) 2003-09-22

Similar Documents

Publication Publication Date Title
ATE432689T1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
NO20061859L (no) OROS Push Stick for kontrollert tilforsel av aktive midler
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
EP1242013A4 (de) Bukkale transmukosale arzneidarreichung unter verwendung einer festen lösung
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
DK1173178T3 (da) Præparat, der omfatter apomorfin og sildenafil, og anvendelse deraf til behandling af erektil dysfunktion
ATE298562T1 (de) Hydrogelpartikel formulierungen
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
EA200300046A1 (ru) Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию
NO20072931L (no) Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
ATE388687T1 (de) Medikamentöse verabreichung von nikotin in form von kaugummi
WO2005055921A3 (en) Compositions for treatment of ear disorders and methods of use thereof
SG146638A1 (en) Pharmaceutical delivery system
NZ507203A (en) Use of dexmedetomidine for ICU sedation
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
WO2002034267A8 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
WO2005010022A3 (en) Agonist polypeptide of receptor for zot and zonulin
SG145717A1 (en) Composition for releasing a weak base for an extended period of time
AR062894A1 (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths)
ATE256134T1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
ATE446309T1 (de) Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
ATE477021T1 (de) 1,3,5-triazepin-dionen zur behandlung von malaria